Uganda Martyrs University Institutional Repository (UMU-IR)
    • Login
    View Item 
    •   UMU-IR Home
    • Research Articles
    • Faculty of Health Science
    • Journal Articles (Health)
    • View Item
    •   UMU-IR Home
    • Research Articles
    • Faculty of Health Science
    • Journal Articles (Health)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Impact of Anthelminthic Treatment in Pregnancy and Childhood on Immunisations, Infections and Eczema in Childhood: A Randomised Controlled Trial

    Thumbnail
    View/Open
    Ndibazza_HSCIE_ARTICLE_2012_Impact of Anthelminthic .pdf (656.8Kb)
    Date
    2012
    Author
    Ndibazza, Juliet
    Mpairwe, Harriet
    Webb, Emily L.
    Mawa, Patrice A.
    Nampijja, Margaret
    Muhang, Lawrence
    Kihembo, Macklyn
    Lule, Swaib A.
    Rutebarika, Diana
    Apule, Barbara
    Akello, Florence
    Akurut, Hellen
    Oduru, Gloria
    Naniima, Peter
    Kizito, Dennison
    Kizza, Moses
    Kizindo, Robert
    Tweyongere, Robert
    Alcock, Katherine J.
    Muwanga, Moses
    Elliott, Alison M.
    Metadata
    Show full item record
    Abstract
    Background: Helminth infections may modulate immune responses to unrelated pathogens and allergens; these effects may commence prenatally. We addressed the hypothesis that anthelminthic treatment in pregnancy and early childhood would improve responses to immunisation and modulate disease incidence in early childhood with both beneficial and detrimental effects. A randomised, double-blind, placebo-controlled trial was conducted in Entebbe, Uganda[ISRCTN32849447]. In three independent randomisations, 2507 pregnant women were allocated to receive single-dose albendazole or placebo, and praziquantel or placebo; 2016 of their offspring were randomised to receive quarterly singledose albendazole or placebo from age 15 months to 5 years. Primary outcomes were post-immunisation recall responses to BCG and tetanus antigens, and incidence of malaria, diarrhoea, and pneumonia; incidence of eczema was an important secondary outcome. Analysis was by intention-to-treat. Of 2345 live births, 1622 (69%) children remained in follow-up at age 5 years. 68% of mothers at enrolment, and 11% of five-year-olds, had helminth infections. Maternal hookworm and Schistosoma mansoni were effectively treated by albendazole and praziquantel, respectively; and childhood hookworm and Ascaris by quarterly albendazole. Incidence rates of malaria, diarrhoea, pneumonia, and eczema were 34, 65, 10 and 5 per 100 py, respectively. Albendazole during pregnancy caused an increased rate of eczema in the children (HR 1.58 (95% CI 1.15–2.17), p = 0.005). Quarterly albendazole during childhood was associated with reduced incidence of clinical malaria (HR 0.85 (95% CI 0.73–0.98), p = 0.03). There were no consistent effects of the interventions on any other outcome. Routine use of albendazole in pregnancy may not always be beneficial, even in tropical developing countries.By contrast, regular albendazole treatment in preschool children may have an additional benefit for malaria control wherehelminths and malaria are co-endemic. Given the low helminth prevalence in our children, the effect of albendazole on malaria is likely to be direct.
    URI
    http://hdl.handle.net/20.500.12280/1368
    Collections
    • Journal Articles (Health) [173]

    UMU-IR
    Contact Us | Send Feedback | Library | Library Catalogue
    Atmire NV
     

     

    Browse

    UMU-IRCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    UMU-IR
    Contact Us | Send Feedback | Library | Library Catalogue
    Atmire NV